ArticleDrug discovery today2015
Impact of recent innovations in the use of mass cytometry in support of drug development.
Article in Drug discovery today, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry: a call for harmonized gating strategies.Frontiers in immunology · 2025Review
- High-Throughput Single-Cell Analysis of Nanoparticle-Cell Interactions.Trends in analytical chemistry : TRAC · 2023Article
- Applications of single-cell RNA sequencing in drug discovery and development.Nature reviews. Drug discovery · 2023Review
- Immune cell profiling in atherosclerosis: role in research and precision medicine.Nature reviews. Cardiology · 2022Review
- Single-Cell Multiomics Analysis for Drug Discovery.Metabolites · 2021Review
- Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches.Clinical reviews in allergy & immunology · 2021Review
- Article
- Identification of ALP+/CD73+ defining markers for enhanced osteogenic potential in human adipose-derived mesenchymal stromal cells by mass cytometry.Stem cell research & therapy · 2021Article
- Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).International journal of oncology · 2018Review
- Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry.PloS one · 2018Article
- Automation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimization.Analytical and bioanalytical chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cytometry by time-of-flight (CyTOF) is a novel technology for the real-time analysis of single cells. CyTOF is a significant advance in fields including immunology, hematology, and oncology. It resolves multiple metal-conjugated probes per cell with minimal signal overlap, which maximizes the information obtained from each individual sample. CyTOF provides the ability to phenotypically and functionally profile cells from normal and diseased states. Single cell technologies enable researchers to measure the effects of a drug at the single cell level and better understand its mechanism of action. Here, we discuss novel instruments for the analysis of individual biological cells, the impact of recent innovations in support of drug development, and the important roles of CyTOF in drug profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.